Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Novartis    NOVN   CH0012005267

NOVARTIS (NOVN)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
12/10/2018 12/11/2018 12/12/2018 12/13/2018 12/14/2018 Date
84.92(c) 86.92(c) 88.04(c) 87.52(c) 87.02(c) Last
5 598 897 6 301 427 6 027 581 4 305 332 3 320 329 Volume
-2.39% +2.36% +1.29% -0.59% -0.57% Change
More quotes
Financials (USD)
Sales 2018 52 250 M
EBIT 2018 12 793 M
Net income 2018 12 452 M
Debt 2018 15 366 M
Yield 2018 3,37%
Sales 2019 53 581 M
EBIT 2019 13 662 M
Net income 2019 8 919 M
Debt 2019 13 587 M
Yield 2019 3,48%
P/E ratio 2018 16,13
P/E ratio 2019 21,92
EV / Sales2018 4,57x
EV / Sales2019 4,42x
Capitalization 223 B
More Financials
Company
Novartis is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales break down by family of products as follows: - pharmaceutical products (67.2%): used to treat cardiovascular, respiratory, and dermatological diseases, gastrointestinal... 
Sector
Pharmaceuticals
Calendar
01/30Earnings Release
More about the company
Surperformance© ratings of Novartis
Trading Rating : Investor Rating :
More Ratings
Latest news on NOVARTIS
12/13NOVARTIS : FDA clears Pear/Sandoz app for opioid use disorder
AQ
12/13NOVARTIS : receives European Commission approval for self-administration of Xola..
GL
12/13NOVARTIS : receives European Commission approval for self-administration of Xola..
AQ
12/12NOVARTIS : FDA approves first prescription mobile app for opioid use disorder, c..
AQ
12/11EUROPE MARKETS: European Markets Rally On Upbeat Data, Trade-talk Hopes
DJ
12/11NOVARTIS : Sandoz and Pear Therapeutics Obtain FDA Clearance for reSET-O to Trea..
AQ
12/11NOVARTIS : Sandoz EpiPen rival will launch in Q1, with lower price tag
AQ
12/11NOVARTIS : Sandoz Inc. and Pear Therapeutics Obtain FDA Clearance for reSET-O(TM..
AQ
12/10NOVARTIS : Sandoz and Pear Therapeutics Obtain FDA Clearance for reSET-O to Trea..
DJ
12/10NOVARTIS : Sandoz Inc. and Pear Therapeutics Obtain FDA Clearance for reSET-O(TM..
PU
More news
Analyst Recommendations on NOVARTIS
More recommendations
Stock Trading Strategies
NOVARTIS - 11/06
Good timing to anticipate a continuation of the trend
BUY
More Stock Trading Analysis
Sector news : Pharmaceuticals - NEC
12/14FDA Approves Herceptin Biosimilar Herzuma
DJ
12/14Johnson & Johnson Closes Down 10.04% After Reuters Report -- Data Talk Update
DJ
12/14ELI LILLY AND : Lilly to Acquire Pre-Clinical Pain Program From Hydra Bioscience..
DJ
12/14THYSSENKRUPP : Incoming Thyssenkrupp CFO Will Prep Conglomerate for Split
DJ
12/14Johnson & Johnson shares nosedive on report it knew of asbestos in Baby Powde..
RE
More sector news : Pharmaceuticals - NEC
Chart NOVARTIS
Duration : Period :
Novartis Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVARTIS
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 94,8 $
Spread / Average Target 8,7%
EPS Revisions
Managers
NameTitle
Vasant Narasimhan Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Werner Kirsch Chief Financial Officer
John Tsai Chief Medical Officer
Srikant Madhav Datar Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS5.61%223 295
JOHNSON & JOHNSON-4.81%356 703
PFIZER23.05%254 040
ROCHE HOLDING LTD.1.38%216 307
MERCK AND COMPANY35.92%198 877
AMGEN10.45%122 391